InMed Pharmaceuticals INM is a global leader in researching, developing, manufacturing and commercializing rare cannabinoids and cannabinoid analogs. The company is focused on the therapeutic benefits of cannabinol (CBN) as a pipeline of cannabinoid-based drug candidates for the treatment of diseases with high unmet medical needs.
InMed is a clinical-stage company with expertise in the development of biosynthesis, IP, manufacturing and GMP scale-up methodologies. In addition to their innovative research in CBN, InMed Pharmaceuticals is also widely known for its Foundations™ technology – a pediatric, patient-friendly cannabinoid delivery system.
Interested in learning more about the Benzinga Cannabis Capital Conference? Get more information here.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.